Edition:
United Kingdom

Kitov Pharmaceuticals Holdings Ltd (KTOV.OQ)

KTOV.OQ on NASDAQ Stock Exchange Capital Market

2.31USD
15 Dec 2017
Change (% chg)

$0.17 (+7.94%)
Prev Close
$2.14
Open
$2.18
Day's High
$2.33
Day's Low
$2.18
Volume
24,288
Avg. Vol
68,056
52-wk High
$3.49
52-wk Low
$1.27

Chart for

About

Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Kitov pharmaceuticals announces receipt of FDA's favorable response to NT219's pre-ind meeting package

* Kitov Pharmaceuticals announces receipt of FDA's favorable response to NT219's pre-ind meeting package

01 Nov 2017

BRIEF-Kitov Pharmaceuticals announces phase III/IV clinical trial for KIT-302 successfully meets primary endpoint

* Kitov pharmaceuticals announces phase iii/iv clinical trial for kit-302 successfully meets primary endpoint, and also demonstrates drug candidate improves renal function

26 Oct 2017

BRIEF-Kitov boosts ownership in Tyrnovo and Oncology platform

* Kitov boosts ownership in Tyrnovo and Oncology platform through exchange of shares for stock

06 Oct 2017

BRIEF-Kitov posts filing by FDA of New Drug Application for KIT-302

* Kitov announces filing by FDA of New Drug Application for KIT-302

02 Oct 2017

BRIEF-Kitov submits new drug application to FDA for KIT-302

* Says ‍company expects that within 60 days FDA will determine whether NDA is complete and acceptable for filing​

31 Jul 2017

BRIEF-Kitov announces results of study demonstrating NT-219 enhanced efficacy of keytruda in immune-oncology preclinical model

* Kitov announces results of study demonstrating NT-219 enhanced efficacy of keytruda in immune-oncology preclinical model

18 Jul 2017

BRIEF-Kitov Pharma enters agreements with investors

* Kitov Pharmaceuticals - entered agreements with investors providing for issuance of 2.4 million ads at purchase price of $1.45 per ADS - SEC filing‍​

11 Jul 2017

Earnings vs. Estimates